213MO Primary endpoint analysis of a randomized phase II of darolutamide or capecitabine in patients with triple-negative androgen receptor-positive advanced breast cancer (UCBG3-06 START trial)
| Autor: | Arnedos, M., Goncalves, A., Pulido, M., Lerebours, F., Tredan, O., Dalenc, F., Guiu, S., Mollon Grange, D., Teixeira, L., Levy, C., Verret, B., Dawood, H.A.S., Augereau, P., Deiana, L., Ladoire, S., Carola, E., Mouret Reynier, M.A., Guyonneau, C., MacGrogan, G., Bonnefoi, H. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S635-S635 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|